US 12,226,406 B2
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Michael D. Kaufman, Waltham, MA (US); Scott Bone, Bend, OR (US); Corey Bloom, Bend, OR (US); and Fred Jordan, Bend, OR (US)
Assigned to Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed by Deciphera Pharmaceuticals, LLC, Waltham, MA (US)
Filed on Aug. 6, 2024, as Appl. No. 18/795,711.
Application 18/795,711 is a continuation of application No. 18/758,007, filed on Jun. 28, 2024.
Application 18/758,007 is a continuation of application No. 18/518,093, filed on Nov. 22, 2023, granted, now 12,064,422.
Application 18/518,093 is a continuation of application No. 18/448,312, filed on Aug. 11, 2023, granted, now 11,903,933, issued on Feb. 20, 2024.
Application 18/448,312 is a continuation of application No. 18/178,789, filed on Mar. 6, 2023, granted, now 11,793,795, issued on Oct. 24, 2023.
Application 18/178,789 is a continuation of application No. 18/148,766, filed on Dec. 30, 2022, granted, now 11,896,585, issued on Feb. 13, 2024.
Application 18/148,766 is a continuation of application No. 17/735,820, filed on May 3, 2022, granted, now 11,612,591, issued on Mar. 28, 2023.
Application 17/735,820 is a continuation of application No. 17/180,241, filed on Feb. 19, 2021, granted, now 11,395,818, issued on Jul. 26, 2022.
Application 17/180,241 is a continuation of application No. PCT/US2020/067560, filed on Dec. 30, 2020.
Claims priority of provisional application 62/968,695, filed on Jan. 31, 2020.
Claims priority of provisional application 62/968,724, filed on Jan. 31, 2020.
Claims priority of provisional application 62/955,073, filed on Dec. 30, 2019.
Claims priority of provisional application 62/955,062, filed on Dec. 30, 2019.
Prior Publication US 2024/0390344 A1, Nov. 28, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4375 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 47/38 (2006.01)
CPC A61K 31/4375 (2013.01) [A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 47/38 (2013.01)] 13 Claims
 
1. A pharmaceutical composition comprising:
a solid dispersion comprising: a compound represented by Formula (I) or pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
and a pharmaceutically acceptable polymer, wherein the pharmaceutically acceptable polymer is hydroxypropylmethyl cellulose acetate succinate; and
one or more anilinic substances, wherein the one or more anilinic substances, is present in an amount equal to or less than about 10% by weight based on the weight of the compound of Formula (I) present in the composition,
and wherein water is present in the composition in an amount of no more than about 6% by weight based on the total weight of the pharmaceutical composition.